Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging ...

CVS Caremark has removed coverage of Zepbound, a GLP-1 weight-loss drug, citing pricing concerns and shifting payer dynamics ...

Do those on Zepbound have to switch to Wegovy after Caremark drops Zepbound from preferred coverage? What options are there?

Starting in August, 12.5-milligram and 15-milligram single doses will be added to the company’s website, effectively making all Zepbound doses available for $499 a month or less.

Even with the CVS formulary change (moving away from Zepbound) putting ~200,000 patients at risk, says the analyst, Eli Lilly's market share — currently around 70-75% of new patients — and ...

Other factors can affect access. This week, CVS Health said Wegovy will become the preferred option on its standard formulary, or list of covered drugs, as of July 1. Zepbound will be excluded.

CVS Health opts for Wegovy and Saxenda on its formulary; Zepbound excluded. Millions affected as coverage choices impact cost and access to obesity drugs.

Other factors can affect access. This week, CVS Health said Wegovy will become the preferred option on its standard formulary, or list of covered drugs, as of July 1. Zepbound will be excluded.

Other factors can affect access. This week, CVS Health said Wegovy will become the preferred option on its standard formulary, or list of covered drugs, as of July 1. Zepbound will be excluded.

Other factors can affect access. This week, CVS Health said Wegovy will become the preferred option on its standard formulary, or list of covered drugs, as of July 1. Zepbound will be excluded.